The liver acts as a manufacturing unit for the production of fetuin-A, which is essential for various physiological characteristics. Scientific research has shown that a moderate upward push in fetuin-A serum levels is associated with a confirmed non-alcoholic fatty liver disease (NAFLD) diagnosis. Fetuin-A modulation is associated with a number of pathophysiological variables that cause liver problems, including insulin receptor signaling deficiencies, adipocyte dysfunction, hepatic inflammation, fibrosis, triacylglycerol production, macrophage invasion, and TLR4 activation. The focus of the present review is on the various molecular pathways, and genetic relevance of mRNA expression of fetuin-A which is correlated with progression of NAFLD. The other major area of exploration in the present review is based on the new targets for the modulation of fetuin-A, like calorie restriction and novel pharmacological agents, such as rosuvastatin, metformin, and pioglitazone which are successfully implicated in the management of various liver-related complications.

肝脏是生产胎球蛋白 A 的制造单位，胎球蛋白 A 对各种生理特性至关重要。科学研究表明，胎球蛋白 A 血清水平适度升高与确诊的非酒精性脂肪性肝病 (NAFLD) 诊断相关。胎球蛋白-A 调节与许多导致肝脏问题的病理生理变量相关，包括胰岛素受体信号缺陷、脂肪细胞功能障碍、肝脏炎症、纤维化、三酰甘油产生、巨噬细胞入侵和 TLR4 激活。本综述的重点是各种分子途径，以及与 NAFLD 进展相关的 fetuin-A mRNA 表达的遗传相关性。